Biogen Initiates Randomized Trial of Lumiliximab for Advanced CLL
Biogen Initiates Randomized Trial of Lumiliximab for Advanced CLL
CAMBRIDGE, MassachusettsBiogen Idec has initiated a randomized, multicenter, registration trial, known as LUCID, of its anti-CD23 monoclonal antibody lumiliximab in combination with fludarabine, cyclophosphamide, and rituximab (FCR) vs FCR alone for patients with relapsed or refractory chronic lymphocytic leukemia (CLL). The antibody was also granted Fast Track and Orphan Drug designation by FDA. In a phase I/II trial reported at the 2006 ASH Annual Meeting, the addition of lumiliximab to the FCR regimen resulted in a 52% complete response rate among CLL patients with progressive disease, the company said.
Articles in this issue
Peptide-Based Breast Ca Vaccines Promising in Early Trials
Diagnostic Dilemma: GI Disease
Imatinib Responses in CML May Take Time
IV Vidaza Approved; Oral Formulation to Be Tested
Study Confirms Avastin Advantage in Advanced NSCLC
Legal Services Should Be a Component of Standard Cancer Care
Mouse Virus Evidence Suggests Viral Basis for Breast Ca
Groups Oppose Ruling on Access to Experimental Drugs
Satellite Allows Digital Mammography Screening for Rural Native Americans
Nexavar Effective in Advanced HCC: Phase III Trial Stopped
H&N Ca Patients With CR to CRT May Not Need Surgery
Two Sets of Researchers Find Herceptin Cost Effective
Family-Based Testing Strategy May Better Detect HNPCC
More 'Promacs,' Worse Outcome
Brachytherapy Balloon Can Be Placed After Final Pathology
Related Videos
Related Content
